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Human IgA binds a diverse array of commensal
bacteria
Delphine Sterlin1*, Jehane Fadlallah1*, Olivia Adams2*, Claire Fieschi3, Christophe Parizot1, Karim Dorgham1, Asok Rajkumar1, Gaëlle Autaa1,
Hela El-Kafsi1, Jean-Luc Charuel1, Catherine Juste4, Friederike Jönsson5, Thomas Candela6, Hedda Wardemann7, Alexandra Aubry1, Carmen Capito6,
Hélène Brisson1, Christophe Tresallet8, Richard D. Cummings9, Martin Larsen1, Hans Yssel1, Stephan von Gunten2, and Guy Gorochov1
In humans, several grams of IgA are secreted every day in the intestinal lumen. While only one IgA isotype exists in mice,
humans secrete IgA1 and IgA2, whose respective relations with the microbiota remain elusive. We compared the binding
patterns of both polyclonal IgA subclasses to commensals and glycan arrays and determined the reactivity profile of native
human monoclonal IgA antibodies. While most commensals are dually targeted by IgA1 and IgA2 in the small intestine,
IgA1+IgA2+ and IgA1−IgA2+ bacteria coexist in the colon lumen, where Bacteroidetes is preferentially targeted by IgA2. We also
observed that galactose-α terminated glycans are almost exclusively recognized by IgA2. Although bearing signs of affinity
maturation, gut-derived IgA monoclonal antibodies are cross-reactive in the sense that they bind to multiple bacterial targets.
Private anticarbohydrate-binding patterns, observed at clonal level as well, could explain these apparently opposing features of
IgA, being at the same time cross-reactive and selective in its interactions with the microbiota.
Introduction
IgA is the second most important isotype in serum, with se-
cretory IgA being predominant in gut lumen, where its functions
range from host-commensal symbiosis to protection against
enteric pathogens. IgA contributes to intestinal homeostasis,
either by directly inhibiting bacterial virulence features or by
shaping microbiota composition and promoting symbiosis be-
tween bacteria (Forbes et al., 2008, 2011; Okai et al., 2016;
Nakajima et al., 2018). Indeed, IgA-deficient mice and humans
show increased susceptibility to gastrointestinal infections and
inflammatory diseases, such as celiac disease or inflammatory
bowel disease (Harriman et al., 1999; Johansen et al., 1999;
Ludvigsson et al., 2016). Gut microbiota drives IgA production,
since germ-free mice show a drastic reduction in mucosal IgA-
secreting B cells (Moreau et al., 1978). Most intestinal commensals
are IgA coated in situ, as shown by combined flow cytometry
sorting and 16S ribosomal DNA sequencing (Kawamoto et al.,
2012; Palm et al., 2014; Bunker et al., 2015; Kau et al., 2015).
IgA predominantly binds colitogenic and commensal bacteria of
the small intestine (Palm et al., 2014; Bunker et al., 2015). Mouse
microbiota-reactive IgA antibodies were shown to target a broad
pattern of commensals at the clonal level (Okai et al., 2016;
Bunker et al., 2017).
Recent observations in mice highlighted a role for several
commensals in the induction of serum IgA, binding in return a
restricted fraction of gut microbiota and providing protection to
polymicrobial sepsis (Wilmore et al., 2018). Humans, unlike
mice, express two subclasses of IgA, IgA1 and IgA2. Whereas
IgA1 is predominant in serum, IgA2 is mainly secreted in mu-
cosal compartments (Chiba et al., 1987; Pakkanen et al., 2010).
The abundance of the two IgA isotypes varies throughout the
intestine (Chiba et al., 1987; Pakkanen et al., 2010). Peyer’s
patches containmore IgA1+ B cells than lamina propria, whereas,
in contrast, colon contains mainly B cells that secrete IgA2, a
subclass endowed with enhanced resistance to the action of
bacterial proteases, as compared with IgA1 (He et al., 2007). In
general, IgA2 class switching occurs through a CD4+ T cell–
independent pathway, while IgA1 requires the activation of
B cells by CD4+ T cells through CD40–CD40 ligand interaction
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and the secretion of TGF-β (He et al., 2007; Coffman et al., 1989).
It is widely accepted that microbial capsular polysaccharides and
lipopolysaccharides are major targets of commensal-specific
antibodies derived from T cell–independent pathways (Bunker
et al., 2015; Stowell et al., 2014). It could thus be speculated that
the IgA2 repertoire might contain a broader spectrum of mi-
crobial carbohydrate–specific antibodies. Overall, the extent to
which each of these two subclasses interacts with intestinal
commensals along the intestine remains enigmatic.
We compared polyclonal reactivity of secretory IgA1 and IgA2
toward ileum and colon human microbiota and further inves-
tigated the specificity of IgA2 at the clonal level. Our results
argue that human IgA antibodies are both promiscuous and
selective in their interaction with the microbiota.
Results
Broad but differential glycan recognition by serum IgA1
and IgA2
To decipher the repertoire of carbohydrate-specific IgA, we used
glycan microarray technology. Comparison of the glycan rec-
ognition profiles of pooled human IgA1 and IgA2 revealed a
broad recognition pattern of carbohydrate structures by both
classes of antibodies, although only 15 glycans were cotargeted
by both IgA1 and IgA2 (Fig. 1, A and B).
The terminal carbohydrate moiety has been shown to be a
critical determinant of glycan-specific antibody responses
(Schneider et al., 2015), which could explain the lack of
overlap of IgA1 and IgA2 carbohydrate repertoires. Glycan
microarray screening of pooled human serum–derived IgG
revealed prominent recognition of galactose-α (Galα)–
terminated glycans, which include major xenoantigens
(Griesemer et al., 2014), but limited binding to sialoglycans
containing human N-Acteylmeuraminic acid (Neu5Ac) or
nonhuman N-Glycolylneuraminic acid (Neu5Gc; Schneider
et al., 2015). Strikingly, Galα-terminated glycans were al-
most exclusively recognized by IgA2 (Fig. 1 C). Preferential
recognition by IgA2 was observed for both Neu5Ac- and
Neu5Gc-terminated sialoglycans, while N-Acetylglucosamine
(GlcNAc)–terminal glycans were equally bound by IgA1 and
IgA2. By consulting the Bacterial Carbohydrate Structure
Database, we determined that among the 610 glycans on the
microarray, 137 structures were identified as bacterial anti-
gens, including 16 Galα-terminated structures. We observed
that bacterial antigens, excluding Galα-terminated structures
(n = 121), had a similar recognition profile when compared
with the entire glycan microarray dataset (Fig. 1 D). Thus, the
overall structure of the glycans has an impact on the induced
IgA1 and/or IgA2 immunogenicity. These results also dem-
onstrate that IgA2 widely recognizes bacterial antigens and
that this phenomenon is more evident for Galα-structures.
Finally, we noticed that 3 out of the 10 host glycans displayed
on the microarray, known to serve as attachment sites for bac-
teria in various mucosal compartments (Schneider et al., 2015),
were preferentially bound by IgA2, as comparedwith IgA1 (Fig. 1 E).
The latter findings support the conclusion that IgA tempers bac-
terial activity, not only through direct interaction with their
surface antigens but also by interfering with their host ligands.
More host attachment sites should be tested in order to deter-
mine whether IgA2 is preferentially involved in recognizing host
glycans used for bacterial adhesion.
The secretory component modestly contributes to
glycan binding
The above study was conducted with serum IgA. However, in
gut lumen, dimeric IgA is associated with the secretory com-
ponent that mediates binding to Gram-positive bacteria irre-
spective of antibody specificity. Using glycan array technology,
we assessed secretory component binding to carbohydrates and
found 27 glycans that were specifically recognized by the se-
cretory component (Fig. S1 A). These results point out that,
in vivo, the secretory component may further enlarge the
spectrum of IgA binding to microbiota; however, the glycan-
binding pattern remains much wider for IgA alone than for
the secretory component.
Gut bacteria are predominantly targeted by IgA2
We observed partial overlap of microbial carbohydrate reac-
tivity between serum IgA1 and IgA2, while IgA2 was found to
exhibit a broader spectrum of microbial specificities. We
attempted to test whether the carbohydrate reactivity patterns
observed with IgA1 and IgA2 reflected microbial recognition
in vivo using bacterial flow cytometry analysis (Moor et al.,
2016). Because gut contains not only the highest concentra-
tion of microbial antigens but also both subclasses of IgA, we
investigated the extent of secretory IgA binding to gut com-
mensals. We used isotype-specific secondary antibodies to
probe naturally IgA-coated microbiota of healthy donors. We
first ruled out cross-reactivity of anti-IgA1 and anti-IgA2 anti-
bodies by probing human B cells that are known to express only
one antibody isotype and determined that virtually no double-
positive cells were present when B cells were incubated with
fluorescent anti-IgA1 and anti-IgA2 antibodies (Fig. S1 B). Using
these reagents, we observed that IgA2 accounted for most
commensal binding in fecal microbiota of healthy donors (Fig. 2
A, upper panel).
Convergent IgA1 and IgA2 responses
While IgA1 bound the same commensal bacteria as IgA2, other
commensals were targeted by the latter isotype only (Fig. 2 A).
Whereas the frequency of IgA2+IgA1+ and IgA2+IgA1− fractions
varied among individuals (1.95% [0.12–7.27%] vs. 3.19%
[0.69–17.99%] of all fecal bacteria; Fig. 2 B), the IgA2−IgA1+
fraction was always negligible (0.08% [0–1.00%]; Fig. 2 B). Flow
cytometry analysis showed that IgA-coated bacteria segregated
into two fractions, depending on median fluorescence intensity:
IgAlow and IgAbright staining. Dual staining by IgA1 and IgA2 was
associated with the IgAbright fraction, whereas the IgAlow fraction
corresponded to IgA2+IgA1− bacteria (Fig. S1 C). Because ileal
Peyer’s patches contained more IgA1+ than IgA2+ B cells
(He et al., 2007), we also profiled total IgA and IgA subclass
binding in ileal contents. As expected (Bunker et al., 2015), we
found higher proportions of IgA-coated microbiota in the ileum
than in the fecal compartment (53.6% [44.6–79.4%] vs. 9.15%
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[1.61–34.6%]; Fig. S1 D). A large proportion of ileal commensals
were bound by both IgA1 and IgA2 (37.4% [19.2–55.2%]; Fig. 2 A,
lower panel), indicating that the convergence of IgA1 and IgA2
responses is compartment independent.
Convergent IgM and IgA responses
We observed significant IgM staining (IgM-coated bacteria
≥1%) in the fecal microbiota of only 5 out of 20 healthy donors
(0.32% [0.04–7.51%]; Fig. 2 C) in line with observations sug-
gesting that IgM binds mucosal (Magri et al., 2017) rather than
luminal (Fadlallah et al., 2018) communities in the colon.
Among these five fecal samples and five other ileal samples, we
searched for IgM, IgA1, or IgA2 overlapping binding. Like IgA-
coated bacteria, IgM-coated bacteria were more abundant in
the ileum. Indeed, the frequency of IgM-coated bacteria ex-
ceeded 20% in three out of five ileal specimens (24.10%
[0.65–74.71%]; Fig. 2 C). We found that IgM-bound bacteria
were also largely bound by both IgA1 and IgA2 (Fig. 2, D–F).
Hence, IgM converges toward IgA-bound microbes, both in the
ileum and in the colon lumen.
IgA2 also predominates in early life
A constant ratio of IgA1 to IgA2 has been reported in serum
throughout childhood, which implies that there is no delay in the
production of one isotype as compared with the other (Schauer
et al., 2003). However, little is known about the establishment of
secretory IgA subclasses in early life. Because analysis of IgA-
coated bacteria is complicated by the presence of breast milk–
derived IgA during the first months of life, we selected fecal
samples from eight formula-fed neonates (mean age: 5 mo; age
range: [3–5] mo) and quantified their proportions of IgA-, IgA1-,
and IgA2-bound microbiota. Like in adults, mostly IgA2+IgA1+
and IgA2+IgA1− bacteria were detected, while IgA2−IgA1+ cells
were rare among neonatal fecal microbiota (3.23% [0.69–6.7%],
3.96% [2.94–32.8%], and 0.08% [0.00–2.08%], respectively;
Fig. 2 G), suggesting that both autologous IgA1 and IgA2 are
Figure 1. Carbohydrate-binding profile of polyclonal IgA1 and IgA2 antibodies. (A) Glycan reactivity of serum polyclonal IgA1 and IgA2 (n = 5 healthy
donors pooled in one experiment). Each peak represents an individual glycan recognized by IgA1 (blue line) or IgA2 (red line). (B) Heatmap diagram depicting
glycans recognized by IgA1 or IgA2. Each row represents an individual glycan. (C) Preferential recognition of distinct terminal carbohydrate moieties by serum
polyclonal IgA1, IgA2, or both. Terminal carbohydrate moieties equally recognized by both IgA1 and IgA2 are depicted in white. Terminal moieties preferentially
recognized by IgA1 or IgA2 are showed in gray or black, respectively. (D) Isotype-dependent recognition of Galα-terminal structures of bacterial origin and
other bacterial antigens excluding Galα-terminal antigens (without Galα) by serum polyclonal IgA, as compared with entire glycan microarray dataset. Terminal
carbohydrate moieties equally recognized by both IgA1 and IgA2 are depicted in white. Terminal moieties preferentially recognized by IgA1 or IgA2 are showed
in gray or black, respectively. (E) Differential isotype binding to bacterial attachment sites.
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involved in the coating of the developing microbiota very early
on. To corroborate these findings, we took advantage of a single
colon tissue specimen obtained from a 3-mo-old infant and
verified its IgA1 and IgA2 B cell content. As expected, lamina
propria IgA2+ B cells were more abundant that IgA2+ B cells in
this sample (1.4% vs. 0.4%; Fig. 2 H). Thus, like in adults, the
IgA2 isotype predominates in infants, although IgA1 neverthe-
less cobinds IgA2-coated bacteria.
Interindividual variability of IgA1- and IgA2-binding profiles
We next analyzed the composition of subclass-bound bacteria in
fluorescence-activated cell-sorted IgA1+ and IgA2+ populations
and identified bacterial species by 16s ribosomal RNA (rRNA)
sequencing. Of note, as all IgA1-coated bacteria were also bound
by IgA2, the IgA1-sorted fraction included only IgA2+IgA1+–coated
bacteria, whereas the IgA2-sorted fraction both contained
IgA2+IgA1+ and IgA2+IgA1− (referred as IgA2+IgA1+/− in the
text), with IgA2+IgA1− bacteria being predominant (IgA2+IgA1−/
IgA2+IgA1+ ratio >2). We first examined the whole microbiota
composition and found interindividual variability at phylum
and genus levels (Fig. S2, B–D). The microbial diversity, as well
as bacterial composition, differed between donors, as shown by
the Shannon index (2.98 [2.85–3.30]; Fig. S2 C). With respect to
the sorted fractions, within a single donor, IgA1 and IgA2
binding identified distinct patterns of bacteria at the family
level. For example, in a given healthy donor, Bifidobacteriaceae
were enriched in the IgA2+IgA1+–coated fraction, while Rumi-
nococcaceae were predominant in the IgA2+IgA1+/−–enriched
fraction, as compared with the whole microbiota of the same
donor (Fig. S2 E). We also noticed interindividual variability of
IgA1- and IgA2-binding profiles at the family level, suggesting
that the preferred targets of IgA1 and IgA2 are dependent on
microbiota composition rather than on microbial phylogeny
(Figs. 3 A and S2 E).
We next focused on the genus level and determined the
breadth of bacteria coated by IgA1 and IgA2 by comparing the
relative abundance of bacteria genera in each of the fractions.
Genera were present at similar frequencies in both IgA2+IgA1+–
and IgA2+IgA1+/−–sorted fractions (median of genera relative
abundance 0.00048 [0.00018–0.0038] vs. 0.0019 [0.00041–
0.00276], respectively, P = 0.81; Fig. 3 B). Moreover, the two
fractions did not significantly differ from input microbiota
in terms of bacterial diversity (Shannon index 2.36 [1.3–
2.88], P = 0.19 vs. 2.31 [1.97–2.86], P = 0.13, respectively; Fig.
S2 C), indicating that both IgA subclasses coat highly diverse
commensals.
Core IgA1+IgA2+ microbiota among an extended IgA2+ bacterial
repertoire
The results thus far indicate that IgA2+IgA1+– and IgA2+IgA1+/−–
sorted fractions are diverse. Their bacterial composition is not only
different between donors (Fig. 3, A and B) but also distinguishes
itself from the input fraction within a single donor (Fig. 3 C).
Thereafter, we narrowed the analysis down to the 19 most fre-
quent genera that were present in ≥80% of the IgA-coated frac-
tions. To unravel IgA subclass specificities for microbes, we
compared IgA2+IgA1+– and IgA2+IgA1+/−–sorted fractions by cal-
culating log-based enrichment indexes (EIs; see calculation details
in Materials and methods). This calculation allows us to deduce
bacteria preferentially targeted by IgA2 alone compared with du-
ally coated bacteria. Eleven genera were preferentially counted in
the IgA1+IgA2+ subset, while eight genera tended to be more fre-
quent in the IgA2+IgA1+/−–coated bacteria (Fig. 3 D). Interestingly,
genera derived from Actinobacteria (Rhodococcus, Bifidobacterium,
and Arthrobacter) were all enriched in dually stained bacteria. In-
stead, genera derived from Bacteroidetes (Prevotella, Flavobacte-
rium, and Bacteroides) were preferentially found in the IgA2+IgA1+/−
fraction (Fig. 3 D), particularly Flavobacterium (IgA2+IgA1+/− EI 1.69
[0.28–2.23] vs. IgA2+IgA1+ EI −0.11 [−2.63 to 0]; P < 0.05; Fig. 3 E).
We sought to validate these observations by staining micro-
biota and representative bacterial strains with IgA purified from
maternal milk. The latter antibodies are more abundant and
might be taken as representative of gut IgA, as in mammary
glands, and IgA plasma cells are mainly derived from gut B cells,
in agreement with the observation that some breast milk anti-
bodies recognize gut antigens (Lindner et al., 2015). Moreover,
flow cytometry analysis is facilitated since breast milk contains
equal quantities of both subclasses, in contrast to free fecal IgAs
that comprise mainly IgA2 (Ladjeva et al., 1989). We first con-
firmed that breast milk–IgA antibodies targeted microbiota from
an IgA-deficient patient (Fig. S3 A).We then confirmed that both
IgA1 and IgA2 bound Bifidobacterium longum, while Bacteroides
vulgatus was only recognized by IgA2 (Fig. 3 F).
Taken together, these results demonstrate that both IgA
subclasses bind a diverse spectrum of commensals. In the small
intestine, IgA1 targets the same commensal bacteria as IgA2 in a
balanced manner, while in the colon, IgA2 preferentially targets
several genera (typically derived from Bacteroidetes).
Figure 2. IgA1 targets IgA2-coated bacteria. (A) Representative flow cytometry analysis of endogenous IgA1 and IgA2 fecal or ileal microbiota coating.
(B) Endogenous IgA1 and IgA2 microbiota coating levels in 20 fecal and 5 ileal healthy samples. Data are cumulative from three independent experiments. Error
bars represent minimum and maximum values. P values were calculated using the Mann-Whitney test (colon vs. ileum) or Wilcoxon test (*, P < 0.05; ***, P <
0.001). (C) Endogenous IgM microbiota coating levels in 20 fecal and 5 ileal healthy samples (two independent experiments). Dark bars indicate medians. Red
dotted line represent significant the positive cutoff. P values were calculated using the Mann-Whitney test (***, P < 0.001). (D) Left: Representative flow
cytometric analysis of endogenous IgM-coated fecal or ileal microbiota. Right: Representative flow cytometric analysis of endogenous IgA1 and IgA2 binding in
IgM-coated fecal or ileal microbiota (two independent experiments). SSC-A, side scatter area. (E) Endogenous IgM microbiota coating levels in 20 fecal and 5
ileal healthy samples (two independent experiments). Error bars represent minimum and maximum values. P values were calculated using the Mann-Whitney
test (**, P < 0.01; *, P < 0.05). (F) Model Venn diagram showing overlap among endogenous IgA1, IgA2, and IgM binding in IgA-coated microbiota. (G) En-
dogenous IgA1 and IgA2 microbiota–coating levels in eight fecal samples from formula-fed neonates (two independent experiments). Error bars represent
minimum and maximum values. P values were calculated using the Wilcoxon test (*, P < 0.05; **, P < 0.01). (H) Flow cytometric analysis of IgA1 and IgA2
expression on colonic lamina propria B cells from a 3-mo-old infant (one experiment).
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Figure 3. IgA1 coordinates with IgA2 to coat distinct commensal bacteria. (A) Median relative abundance of the four most frequent families in sorted
fractions from five healthy donors. Each dot represents one donor. Boxes extend from the 25th to the 75th percentiles. Error bars represent minimum and
maximum values. (B) Median relative abundance of genera from IgA1+IgA2+ and IgA2+ fractions from five healthy donors. Each dot represents one donor.
(C) Relative abundance of indicated top 19 most abundant genera in sorted fractions from one healthy donor. (D) Specificity of IgA subclass targeting for all
individuals analyzed (n = 5). Number of samples in which a given genera had a positive indicated IgA subclass EI, divided by the total number of samples. The
formula is detailed in Materials and methods. (E) Flavobacterium enrichment in IgA2+ as compared with IgA1+IgA2+ fractions. Each dot represents one donor. P
values were defined using the Wilcoxon test (*, P < 0.05). (F) Binding of purified breast milk IgA to indicated bacterial strains. Monoclonal IgA isotype control
(gray-filled histogram) was included as negative flow cytometry control. The same experiment was repeated twice. ns, not significant.
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Both IgA1 and IgA2 induce cytokine production
Because IgA1 simultaneously binds IgA2-coated bacteria, we
investigated whether IgA1 and IgA2 differ in their function.
Several compelling arguments support a role of IgA through
FcαRI expressed on monocytes and macrophages in mucosal
immunity (Aleyd et al., 2015; Hellwig et al., 2001; Balu et al.,
2011). We therefore determined how IgA subclass opsonization
affected the production of cytokines by macrophages. We se-
lected Staphylococcus haemolyticus as a common commensal
recognized by both IgA1 and IgA2 (Fig. 3 D) and incubated free or
IgA-opsonized bacteria with monocyte-derived macrophages. In
accordance with previous reports (Hansen et al., 2017), we ob-
served that IgA opsonization strongly enhanced cytokine pro-
duction by these cells (Fig. S3 B). Both IgA1 and IgA2 increased
the production of IL-6 and TNF-α, yet IgA1 tended to induce
more IL-10 than IgA2.
Human gut lamina propria–derived monoclonal IgA
Colonic bacteria are thus predominantly bound by the IgA2
isotype. To address the issue of IgA2 specificity for human gut
microbiota at a single-cell level, we generated fully human IgA
mAbs derived from the colonic lamina propria of three healthy
donors. We transduced highly purified intestinal IgA+ memory
B cells with a Bcl-6/Bcl-xL–expressing retrovirus (Kwakkenbos
et al., 2010), resulting in the establishment, under limiting di-
lution conditions, of long-term clonal B cell cultures (Fig. S4 A).
Each B cell line was self-renewing and showed a stable expres-
sion of IgA and the activation markers CD38 and CD95 for the
duration of the study (Fig. S4 B). Eight monoclonal IgA anti-
bodies of unrelated sequences (Table S1) were detected as di-
meric IgA in culture supernatants (Fig. S4 C). Previously
characterized monomeric human IgA2 clones directly obtained
by single-cell PCR amplification of the variable Ig genes of iso-
lated colonic cells (Benckert et al., 2011) were also tested.
Discrete bacterial populations are brightly stained by
gut-derived IgA antibodies
To characterize the commensal reactivity of these IgA mAbs in
the absence of competing interference by naturally occurring
IgA, we selected an IgA-deficient microbiota (coined “A”) in
order to probe antibody–bacteria interactions. It has previously
been shown that microbiota complexity is maintained in IgA-
deficient patients, without massive perturbations of gut luminal
microbes (Fadlallah et al., 2018). All eight IgA mAbs bound re-
stricted microbiota fractions (Fig. 4, A and B). However, both
staining intensity (range of median fluorescence intensity,
2,080–10,724) and frequency of bound bacteria (0.79–1.66% of
mAb-coated bacteria) differed between mAbs. Neither the fre-
quency of mAb-coated bacteria nor that of somatic mutations
was correlated with the staining intensity (Fig. 4 C).
IgA binding to microbiota is mostly Fab mediated
To test whether gut-derived IgA mAbs interacted in a Fab or Fc-
dependent manner, we first tested an irrelevant human anti-
TNP IgA. The latter did not bind to microbiota, suggesting that
gut-derived antibody binding might be mostly Fab mediated
(Fig. 4 A). However, we speculated that the anti-TNP IgA used
could possibly bear a different glycosylation pattern compared
with gut-derived IgA that may account for its lack of microbiota
interaction. We therefore also investigated gut IgA2 mAbs
bearing IgG1 constant domains (Benckert et al., 2011). Before
measuring their reactivity to microbiota, we first ruled out the
presence of IgG-bound bacteria in another IgA-deficient mi-
crobiota (microbiota B), in agreement with the lack of IgG
transport to the intestinal lumen (Fig. S4 D). Although their
microbiota avidity might be lower as compared with parental
dimeric IgA, all but one IgA2 Fab/IgG1 Fc monomeric chimeras
bound fecal microbiota (0–1.13% of mAb-coated bacteria; Fig. 4,
D and E). In line with results obtained with dimeric IgA mAbs
(Fig. 4 C), the frequency of monomeric mAb-coated bacteria was
not correlated with staining intensity (Fig. 4 F). Together, these
results demonstrate that the IgA mAbs tested bind microbiota in
a Fab-dependent manner.
Intestinal IgA clones target highly diverse commensal bacteria
To identify commensal bacteria bound by individual monoclonal
IgA, we characterized mAb-bound (mAb+) sorted fractions by
16S rRNA gene sequencing (Fig. 4 G). All mAbs tested recognized
the four major phyla, namely Actinobacteria, Bacteroidetes,
Firmicutes, and Proteobacteria, but each one exhibited a unique
binding profile (Fig. 4 H). Genus-level analysis corroborated
these distinct binding patterns and highlighted IgA cross-
reactivity with numerous genera, irrespective of their micro-
bial phylogeny (Fig. 4, I and J). Both series of mAbs, generated
either with IgA2 or IgG1 Fc domain, bound various genera
(Fig. 4, I and J). These data therefore indicate that a single IgA
might recognize a wide panel of bacteria. Because mAb reac-
tivity extended to unrelated genera, we tested whether genus
abundance might influence mAb-binding patterns. We found
that genera in mAb+ and mAb− fractions did not differ in terms
of relative abundance (median of genera relative abundance
0.00123 [0.000284–0.0056] in the mAb+ fraction vs. 0.0008
[0.00026–0.00159] in the mAb− fraction, P = 0.27; Fig. 4 K).
Moreover, 12 out of the 50 most abundant genera (Eggerthella,
Bacteroides, Parabacteroides, Anaerostipes, Kingella, Neisseria, and
Pelomonas in microbiota A and Tissierella, Peptostreptococcus,
Paenibacillus, Microbacteriuma, and Helcococcus in microbiota B)
were not targeted by the tested mAbs (Fig. S4, E and F), thereby
implying that IgA antibodies react with various commensal
microbes regardless of their bacterial richness. As expected,
mAb-binding profiles included Ruminococcus, Roseburia, Clos-
tridium, and Blautia previously described as common IgA targets
in humans (Fig. 4, I and J; D’Auria et al., 2013; Palm et al., 2014;
Magri et al., 2017).
IgA clones exhibit private microbiota-binding patterns
The mAb-binding patterns were characterized in a quantitative
manner by calculating a log-based EI at the genus level, followed
by the application of a hierarchical clustering algorithm (Fig. S4,
E and F). All mAbs were highly cross-reactive against a median
of 19 genera among the 50most abundant (range, 8 to 27; Fig. S4,
E and F). Neither the frequency of somatic mutations nor the
staining intensity correlated with the number of target genera,
according to positive EIs. In addition, EIs varied among the target
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Figure 4. Human monoclonal IgA target highly diverse commensal bacteria. (A) Representative flow cytometry plot of microbiota reactivity for mAb#2
and human IgA2 anti-TNP. mAbs 1–8 are gut monoclonal IgA2 expressed as dimeric IgA. SSC-A, side scatter area. (B)mAb coating of IgA-free microbiota. mAbs
are classified in increasing fluorescence intensity order (median fluorescence intensity [MFI], range 2,080–10,724). The same experiment was repeated twice.
(C) Somatic mutations of mAbs are not correlated to IgA staining intensity. Somatic mutations in the V-region of IGH gene were analyzed. Nonparametric
Spearman correlation was calculated. (D) Representative flow cytometry plot of microbiota reactivity for mAb 10 and human IgG1 anti-TNFα. mAbs 9–16 are
gut monoclonal IgA2 expressed as IgG1 (Benckert et al., 2011). (E) mAb coating of IgA and IgG-free microbiota. MAbs are classified in increasing fluorescence
intensity order (MFI, range 3,585–17,683). The same experiment was repeated twice. (F) Somatic mutations of mAbs are not correlated to mAb staining
intensity. Somatic mutations in V-region of IGH gene were analyzed. Nonparametric Spearman correlation was calculated. (G)mAb+ and mAb− fractions of IgA-
free gut microbiota were sorted by flow cytometry, and their composition was analyzed by 16S rRNA sequencing. (H) Relative abundance of phyla in whole
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genera of the mAbs, indicating that they might bind variant
generawith different affinities. Higher EIs could also be accounted
for, in case a mAb recognized more species within a genus.
To confirm the validity of the mAb targets identified by 16S
rRNA sequencing, we also compared mAb IgA binding to rep-
resentative bacterial strains isolated from human fecal samples.
We previously calculated that only mAbs 1, 2, 3, 9, and 10 were
associated with positive Staphylococcus EIs, while mAbs 4 and 7
were not. Accordingly, the latter two clones did not bind Sta-
phylococcus aureus or S. haemolyticus (Fig. S4 G). Interestingly,
while mAbs 1, 2, and 3 indeed bound both bacteria, mAbs 9 and
10 only bound S. haemolyticus, supporting the conclusion that
some IgAs, such as mAbs 9 and 10, target only distinct species
within a genus.
In summary, we conclude that IgA clones recognize a broad
spectrum of commensal species regardless of their phylogeny,
while each of the mAbs generated in the present study exhibited
a private binding profile.
Private glycan cross-reactive patterns of IgA clones
We hypothesized that shared structures between numerous
bacterial species could contribute to the observed IgA cross-
reactivity. Commensal bacteria express a wide diversity of
glycans, and it is frequently assumed that bacterial surface
carbohydrates are among the common targets of intestinal IgA
(Bunker et al., 2017). Moreover, glycosylation is a very common
posttranslational modification that might create shared epitopes
between various bacterial species, independently of their phy-
logeny (Grangeasse et al., 2015; Macek et al., 2008; Bastos et al.,
2017). We therefore extended our analysis by screening human
IgA mAbs on a glycan microarray displaying 660 different
synthetic carbohydrate structures. Fig. 5 A illustrates the bind-
ing profile for mAb 1 expressed as mean relative fluorescence
units (RFUs). For 17 glycans, for which binding was above
background, the antibody-binding ratio (ABR) of human IgA
mAbs was calculated relative to an isotype-matched control
mAbs, followed by hierarchical clustering analysis (Schneider
et al., 2015). Five glycan structures were specifically recog-
nized by the mAbs tested (Fig. 5, B and C). It is noteworthy to
mention that three out of the five structures are epitopes of
known bacterial origin (Sugahara et al., 1979; Arbatsky et al.,
2000; Bystrova et al., 2000; Tsepilov and Beloded, 2015). Only
two glycans, 804 (Galβ1-1GlcNAcβ-OCH2CH2)2 and 630
(GlcAβ1-3GlcNAcβ1-4)20, were bound by all mAbs, albeit with
different intensities. These results do not imply that IgA2 would
only bind glycan antigens, but interestingly, all mAbs tested
were glycan cross-reactive. Concurrently, each IgA2 clone tested
exhibited a unique glycan-binding pattern.
Bacterial glycans contribute to the IgA–microbiota interaction
The observations described above confirmed that IgA exhibits
bacterial and glycan cross-reactivity but do not infer that IgA
binding to microbiota is mainly due to glycan recognition. To
evaluate whether glycans indeed play a role at the IgA–
microbiota interface, we sought to compare IgA binding to mi-
crobiota before and after deglycosylation. As shown in Fig. 5 D,
enzymatic procedure removal of glycans on gut bacteria resulted
in a marked drop in the interaction with monoclonal IgA (me-
dian % of decrease and range: 23 [15–28]), indicating a contri-
bution of carbohydrates in the binding. Since much remains to
be uncovered concerning glycosylation in prokaryotes, we as-
sumed that the panel of enzymes we used on whole microbiota
likely lead to only partial deglycosylation of the latter and a
possible underestimation of glycan involvement with IgA
binding.We therefore further explored the role of glycans in IgA
binding at the bacterial strain level. Since mAbs 9 and 10 rec-
ognized S. aureus, but not S. haemolyticus (Fig. 5 E), we purified
their surface glycans and found that both mAbs bound purified
peptidoglycan (PG), but not teichoic acid (TA) from S. aureus. As
expected, no binding to S. haemolyticus PG was observed. To-
gether, these observations confirm that glycans do play a role in
IgA binding to microbiota.
Cross-reactive IgA bear features of antigen-driven affinity
maturation
The above observations all support the view that IgA binds di-
verse bacterial species. This cross-reactive pattern raised the
question of IgA affinity maturation. Cross-reactive antibodies
are thought to derive from T cell–independent responses, which
generate low-affinity antibodies, referred to as “innate” anti-
bodies, as compared with “classical” antibodies that are thought
to originate from T cell–dependent responses, exhibiting both
elevated numbers of somatic mutations and high affinity (Pabst,
2012). We observed high numbers of somatic mutations in the Ig
gene encoding the variable heavy (VH) chain domain of the IgA
clones tested. As shown, higher ratios of nonsilent to silent
mutations in the complementary-determining regions (CDRs)
1 and 2 (median 5.5 [0–29.5]) than in the framework regions
(FWRs) 1–3 (median 2.3 [0.3–15]; Fig. S5 A) are consistent with
an antigen-mediated selection process. Thus, in the gut, the af-
finity maturation process gives rise to cross-reactive IgA.
A fraction of gut-derived IgA is self-specific
Self-reactive IgA+ plasmablasts account for ≤15% of the normal
intestinal plasmablast population (Benckert et al., 2011). To de-
termine whether the microbiota-reactivemAb tested heremight
also react with self-antigens, we performed indirect immuno-
fluorescence assays with the human epithelial cell line HEp-
2000. We first established, as a positive control, that free fecal
IgA reacted with nuclear antigens expressed by HEp-2000 cells
(Fig. S5 B), thereby confirming that under homeostatic con-
ditions, some intestinal B cells do secrete antibodies with spec-
ificity for self-antigens. However, among the 16 mAbs tested,
only one showed a nuclear staining pattern (Fig. S5 B).
microbiota (input) and mAb+ fractions. Microbiota A is IgA-free, while microbiota B is IgA- and IgG-free. 16S rRNA sequencing data were from two independent
experiments. (I) Relative abundance of genera in whole microbiota A (input) and mAb+ fractions. (J) Relative abundance of genera in whole microbiota B (input)
and mAb+ fractions. (K) Scatter dot plot of median relative abundance of genera from mAb+ and mAb− fractions. ns, not significant.
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Collectively, these results suggest that intestinal IgA favors mi-
crobiota reactivity over self-antigens.
Discussion
In the present study, we show that human intestinal IgA binds,
at the clonal level, a wide subset of microbiota, including com-
mensals from the four most frequent phyla. This reactivity ex-
tended to numerous genera, regardless of their phylogenetic
distance or their relative abundance. 1 out of 16 mAbs that were
generated from intestinal B cells displayed both microbiota-
reactivity and self-reactivity, resembling the proportion of 15%
self-reactive plasmablasts described in the lamina propria
(Benckert et al., 2011). While the molecular basis for this broad
antibody reactivity spectrum remains unclear, it has been pro-
posed that IgA bindingmay involve different affinity interactions
with variant antigens of commensal species (Pabst, 2012). Al-
thoughwe could not reliablymeasure the affinity of antibodies to
Figure 5. Microbial surface glycans are common targets of gut human IgA. (A) Glycan reactivity for five mAbs (5 µg/ml) was assessed using glycan
microarray technology (660 structures). Representative median RFUs of mAb1 are shown. Glycan ID numbers of top-bound glycans are indicated. (B) The
median RFUs for top-bound glycans (above background) are shown for all five mAbs tested. (C) The ABR of glycans showing positive reactivity (above
background, as in I) was calculated using an isotype control and visualized in an ordered (by dendrogram algorithm) reactivity matrix (heatmap). Each column
represents a glycan. Color key is shown. (D) Representative flow cytometric dot plot of microbiota-reactivity for mAb 6 after whole-microbiota enzymatic
deglycosylation (left). Decrease of mAb binding to microbiota after enzymatic deglycosylation (right). Columns and error bars represent median and maximum
values, respectively. The same experiment was repeated twice. SSC-A, side scatter area. (E) Representative dot blots of purified PG and lipoteichoic acid (TA)
from S. aureus and S. haemolyticus probed with irrelevant IgG1 (anti-TNFα IgG1), mAb 9, and mAb 10 (gray, red, and green circles, respectively). mAbs 9 and 10
were generated with IgG1 Fc domain. The same experiment was repeated twice.
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bacterial cells, we observed (1) a wide scale of staining intensity
and (2) variations across EIs in mAb+ fractions that strongly
support low- to high-affinity interactions with commensals. Of
note, IgA cross-reactivity does not imply random interactions; on
the contrary, IgA interactions appeared rather selective, since,
for instance, S. haemolyticus evaded some, but not all, IgA anti-
bodies that target S. aureus.
Recent studies report the identification of highly abundant
clonotypes in peripheral memory, as well as lamina propria,
B cells that are cross-reactive (Lee et al., 2016; Rollenske et al.,
2018). Quite remarkably, these antibodies are extensively mu-
tated. Here, we found somatic mutation rates comparable to
those of IgA+ memory B cells (Berkowska et al., 2011, 2015).
Furthermore, replacement/silent ratios point to an antigen-
mediated selection, indicating that intestinal cross-specific IgA
are likely to originate from an affinity-maturation process. We
therefore hypothesize that somatic mutations contribute to the
breadth of commensals bound by intestinal IgA, even though
reverted murine mAbs were reported to remain poly- and mi-
crobiota reactive (Bunker et al., 2017). Consistent with this
hypothesis, germline counterparts of human cross-reactive an-
tibodies against Klebsiella pneumoniae reportedly lose their binding
signature (Rollenske et al., 2018).
It has been previously shown that mouse IgA antibodies react
with carbohydrate epitopes (Peterson et al., 2007; Bunker et al.,
2017). Our glycan microarray screening data corroborate and
extend these observations to humans and further reveal that IgA
(in particular IgA2) antibodies recognize a broad range of gly-
cans. Although glycan microarray technology allows for a large
number of carbohydrate moieties to be simultaneously assessed,
it is still representative of a relatively narrow subset of naturally
occurring glycans. In this light, it is remarkable that we ob-
served specific positivity for all human IgA mAbs tested, and the
observed glycan cross-reactivity is of considerable significance
as well. Indeed, glycosylation is a key posttranslational protein
modification that has the capability to modulate protein inter-
actions, and the comprehension of this process might provide
insight into evolutionary conservation. Studies relating to bac-
terial protein posttranslational modifications have identified
striking similarities across species, despite their phylogenetic
distance (Macek et al., 2008; Grangeasse et al., 2015), reminis-
cent of our finding that IgA-derived mAbs bind bacteria across
genera. While phylogenetically closer species present more
overlapping posttranslational modifications, environmental
cues modulate them among bacteria (Macek et al., 2008;
Grangeasse et al., 2015; Bastos et al., 2017). It seems likely that
intestinal conditions influence alterations in protein posttrans-
lational modifications with effects on bacterial fitness and bac-
terial immunogenicity (Ribet and Cossart, 2010; Butler et al.,
2015). Likewise, the gut environment might favor posttransla-
tional pathways that enhance IgA–microbiota interactions.
Our observations raise the issue of the respective functional
roles of IgA1 and IgA2 and the respective impact they may have
onmicrobiota diversification along the gastrointestinal tract.We
show that both IgA1 and IgA2 induce the production of proin-
flammatory cytokines, while the regulatory cytokine IL-10 was
preferentially induced by IgA1-coated bacteria in vitro (Fig. S3).
While IgA2+IgA1+ bacteria are predominant in the ileum, we
observe that IgA2 accounts for most colonic commensal binding.
Three genera belonging to the phylum Bacteroidetes (Bacteroi-
des, Prevotella, and Flavobacterium) are preferentially recognized
by IgA2 in the stool samples. One tentative explanation for this
finding might be the longer transit time and the availability
of complex polysaccharides in the colon that facilitate the
growth of anaerobes such as Bacteroidaceae and Prevotellaceae
(Donaldson et al., 2016). In contrast, bacteria coated by both IgA1
and IgA2, such as Clostridium species, and additional genera from
Actinobacteria (e.g., Bifidobacterium) and Proteobacteria phyla
(e.g., Serratia), are rather small intestine residents (Sekirov
et al., 2010; Donaldson et al., 2016). These observations suggest
that both IgA1 and IgA2 responses are elicited in the small in-
testine, while the colon would be the dedicated site for IgA2
responses. Bacteria coated by both subclasses in the colon may
represent bacteria originating from the ileum. Indeed, while
IgA1+ and IgA2+ B cells are found in similar proportions in the
small intestine, IgA2+ B cells are preponderant in the colon (He
et al., 2007). One could therefore speculate that IgA2 is essential
for diversification of the colonic microbiota, whereas IgA1 is
preferentially induced in the ileum.
IgA1 and IgA2 identified distinct patterns of bacteria within a
single donor (Fig. 3 C), yet the five healthy donors analyzed in
this study only share isotypic-binding trends (Fig. 3 D). The
sorting strategy we adopted (i.e., comparing IgA1- and IgA2-
sorted cells) introduced crude data noise, as IgA2-sorted cells
are necessarily a mixture of IgA2+IgA1+ and IgA2+IgA1− bacteria.
Although the calculation of an EI allows us to deduce isotypic
trends, not all subclass targets might have been described in this
setting. The high interindividual variability in microbiota com-
position might also have precluded the identification of more
common IgA1 vs. IgA2 targets. However, whereas this indirect
sorting approach may, to a certain extent, dilute the signal, it
does not invalidate any of the positive results that have been
detected. Future work combining more precise sorting (i.e.,
IgA2+IgA1+ vs. IgA2+IgA1− pure populations) in a larger healthy
donor cohort might therefore identify more bacteria with
differential isotype targeting.
Homeostatic secretory IgM responses have been described in
humans, but not in mice. Secretory IgM targets a fraction of
mucus-embedded commensals that are also coated by IgA in the
human colon and ileum (Magri et al., 2017). These observations
notwithstanding, we could detect fecal IgM-bound bacteria in
luminal content of only 5 out of 20 healthy donors, underscoring
the presence of an IgM-bound bacterial gradient from the epi-
thelium to the lumen. IgMmay help IgA to localize bacteria to be
targeted in a favorable habitat in mucus. Indeed, IgM-bound
bacteria are also recognized by IgA1 and IgA2. Consistent with
this finding, Magri et al. noticed that IgM coats IgAbright bacteria
(Magri et al., 2017).
The mAbs tested for glycan reactivity were all of the IgA2
isotype. In an effort to better understand the molecular basis of
the overlapping specificities of IgA1 and IgA2, we performed a
comprehensive investigation of the IgA anticarbohydrate rep-
ertoire and highlighted a specialization for IgA2 in carbohydrate
responses. Our analysis reveals a nonrandom association of
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glycan structural features with immunogenicity, especially di-
rected against the monosaccharide moiety at the terminal po-
sition. High immunogenicity observed for glycans with terminal
Galα is interesting, because this may reflect an important role
for IgA2 in response to the microbiota. The finding that both
Neu5Ac, a self-antigen, and Neu5Gc, a xenoantigen, showed sim-
ilar binding profiles for IgA could possibly be explained by the
structural similarity of the two sugars. It also supports the notion
that terminal carbohydrate moieties influence the balance be-
tween immune response and tolerance, IgA being consideredmore
tolerogenic than proinflammatory (Pasquier et al., 2005; Rossato
et al., 2015). These results obtained by comparing serum IgA1 and
IgA2 remain to be confirmed at the gut secretory IgA level.
In summary, we show that although IgA induction is anti-
gen dependent with highly mutated memory clonotypes, IgA
microbiota-binding patterns are broad but nevertheless clono-
type specific. Similarly, at the polyclonal level, IgA2 and IgA1
targets are broad and partially overlapping, particularly in the
ileum, where IgA2+IgA1+ bacteria are prevalent among IgA-
bound microbiota. In all cases, glycan reactivity accounted not
only for the observed cross-reactivity but also for selectivity.
IgA2 and IgA1 anticommensal responses are observed as early as
3 mo after birth, suggesting that both isotypes are induced
during initial gut colonization by healthy microbiota.
Materials and methods
Human specimens
Surgical samples from histologically normal ascending colon
were obtained from colon cancer patients (Table S2) undergoing
hemicolectomy (Department of Surgery, Pitié-Salpêtrière Hos-
pital, Paris, France). Patients with a history of intestinal in-
flammationwere excluded from the study. Ileostomy fluids were
collected from intensive care unit patients (Table S2). Fresh stool
and blood samples were collected from 20 healthy volunteers
(Fadlallah et al., 2018). Fresh stools from three IgA deficient
patients with undetectable serum IgA levels (<0.07mg/ml) were
obtained from the Department of Clinical Immunology at Saint-
Louis Hospital, Paris (Fadlallah et al., 2018). Antibiotic therapy
or diarrhea in the last 3 mo were exclusion criteria in all in-
stances. Maternal milk was obtained from three healthy donors.
Stool samples, maternal milk, and plasma were immediately
frozen after collection and stored at −80°C until use. All in-
dividuals signed awritten consent and the protocol was approved
by the local ethical committee of the Pitié-Salpêtrière Hospital.
Stool processing and microbiota purification
Fresh feces were aliquoted in a CO2-rich/O2-low atmosphere and
stored at −80°C. Then microbiota were isolated by gradient
purification under anaerobic conditions, as previously described
(Juste et al., 2014). In brief, a density gradient of Nycodenz so-
lution was prepared. Then, thawed stool was diluted in 1X-PBS
(Eurobio), 60% Nycodenz, and 0.03% sodium deoxycholate and
loaded on the gradient. After ultracentrifugation (45 min, 14,567
×g, 4°C; Beckman Coulter ultracentrifuge), fecal bacteria were
extracted and washed three times in 1X-PBS and 0.03% sodium
deoxycholate and centrifuged. The final bacterial pellet was
diluted in 1X-PBS-10% glycerol, immediately frozen in liquid
nitrogen, and stored at −80°C.
Bacterial strains and culture conditions
Staphylococcus epidermidis, S. aureus, and S. haemolyticus were
isolated from human stool samples and identified by Matrix
Assisted Laser Desorption Ionization–Time of Flight (MALDI-TOF)
mass spectrometry (Microbiology department, Pitié Salpêtrière
Hospital, Paris). B. longum (E194v variant A) and B. vulgatus
(NCTC11154) were collected and characterized at the Institut
National de Recherche Agronomique (Jouy en Josas, France).
Bacterial strains were cultured on sheep red blood agar plates at
37°C under aerobic (Staphylococcus sp., for 24 h) or anaerobic
(B. vulgatus for 24 h and B. longum for 48 h) conditions. Indi-
vidual colonies were picked, suspended in 1X-PBS-10X glycerol
(109 CFU/ml), and frozen at −80°C. Quantification of CFUs was
performed by adding counting beads (Beckman Coulter) to
bacterial suspensions on a flow cytometer (FACS Canto II; BD
Biosciences).
Production of human mAbs
For IgA production from long-term clonal B cell cultures, B cells
were isolated from colonic lamina propria, dissected into 2-mm
pieces, digested by the addition of collagenase in 1X-PBS (50mg/
ml; Roche), and then incubated at 37°C for 40 min. Lymphocytes
were purified by centrifugation over Ficoll 400 (Eurobio) and
stained with the following antibodies: anti-CD45 APC-H7, anti-
CD19 BV421, anti-IgD FITC, anti-IgM BV605, anti-CD27 PE-Cy7
(all purchased from BD Biosciences), and anti-IgA PE (Jackson
ImmunoResearch). Dead cells were excluded with LIVE/
DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen).
CD45+CD19+CD27+IgD−IgM−IgA+ B cells were sorted on a FACS
Aria II cytometer (BD Biosciences). B cells were cultured for 4 d
in the presence of irradiated (50 Gy) mouse fibroblasts ex-
pressing CD40L at a concentration of 104 cells per well (Arpin
et al., 1995) and recombinant IL-21 (50 ng/ml, a kind gift of Dr.
Arjen Bakker, AIMM Therapeutics, Amsterdam, Netherlands) in
IMDM (Life Technologies), containing 10% FCS (Biowest) in a 96-
well flat bottom plate. Retroviral transduction was performed
with a Bcl-6– and Bcl-xL–expressing retroviral construct (AIMM
Therapeutics) using experimental conditions described previ-
ously (Kwakkenbos et al., 2010). Briefly, activated B cells were
incubated with retroviral supernatant and polybrene (final
concentration, 4 µg/ml; Sigma-Aldrich) in a 96-well flat bottom
plate, coated with the recombinant human fibronectin fragment
CH-296 (Takara) for 8 h at 37°C. After washing, the cells were
cultured for 4 d in the presence of irradiated CD40L-expressing
mouse fibroblasts and recombinant IL-21 (50 ng/ml) in IMDM-
10% FCS in 96-well flat bottom plates. Transduction efficiency
based on GFP expression was monitored at day 4. B cells clones
were then obtained by limiting dilution cultures, and IgAs were
concentrated from culture supernatants with Amicon centrifugal
filters (Millipore).
Human mAbs obtained through single-cell PCR processing of
isolated IgA-producing colonic lamina propria B cells expressed
variable IgA domains fused to human IgG1 constant domains in
HEK293T cells, as previously described (Benckert et al., 2011).
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Ig gene sequence analysis
RNA extracted from B cell lines (Trizol; Ambion) was reverse
transcribed using random primers and SuperScript III (In-
vitrogen). Oligonucleotides used for VH and VL PCR are de-
scribed in Table S3. Purified PCR products (GeneJET PCR
Purification kit; Thermo Fisher Scientific) were sequenced (ABI
Prism 3730) and analyzed using the ImMunoGeneTics infor-
mation system (http://www.imgt.org). Frequencies of nonsilent
to silent mutations in CDR1-CDR2 and FWR1-FWR3 were cal-
culated for the IGH chain gene based on the total number of
nucleotides analyzed.
Bacterial flow cytometry
mAb binding to microbiota was assessed by bacterial flow cy-
tometry assay, as previously described (Moor et al., 2016). All
buffers were passed through sterile 0.22-µm filters before use.
Briefly, thawed microbiota or bacterial strains (106/condition)
were fixed in 500 µl paraformaldehyde (4% in 1X-PBS) and
stained with Cell Proliferation Dye eFluor 450 (eBioscience) for
25 min at 4°C. After washing with 1X-PBS (10 min, 4,000 ×g,
4°C), bacteria were suspended in 1X-PBS, 2% BSA (Sigma-
Aldrich), 0.02% sodium azide (Sigma-Aldrich) in a 96-well
V-bottom plate. mAb or human monoclonal anti-TNP IgA (a
kind gift of Dr Jönsson, Institut Pasteur, Paris, France) was added
in a 96-well V-bottom plate at a final concentration of 1 µg/ml,
and the plates were incubated for 30 min at 4°C. After washing,
goat anti-human IgA FITC (1/400) or isotype control (both from
Jackson ImmunoResearch) were incubated for 20 min at 4°C.
mAbs bearing an IgG-Fc portion were detected with goat anti-
human IgG-A647 (1/400; Jackson ImmunoResearch). Quantifi-
cation of in vivo IgA1 and IgA2 binding was performed in the
same way. Fixed microbiota were incubated with mouse anti-
human IgA1-FITC and mouse anti-human IgA2 Alexa Fluor 647
(Southern Biotech) or isotype controls for 20 min at 4°C. For
IgA1 and IgA2 binding to pure bacterial strains, purified IgA
from breast milk (final concentration, 10 µg/ml) was added to
106 CFU of B. vulgatus and B. longum for 30 min at 4°C before the
addition of anti-IgA1 and anti-IgA2 secondary antibodies. Then,
bacteria were washed and resuspended in sterile PBS. Samples
were run using a BD FACS Canto II, and 30,000 bacterial events
were acquired. Analysis was performed with FlowJo software
(Tree Star). Medians of fluorescence were used to measure
mAb-binding levels for pure strains.
The same procedure was performed to assess the role of gly-
cans in mAb binding to microbiota. Prior to fixation, thawed mi-
crobiota (106 bacteria/condition) were incubated with a cocktail of
enzymes (PNGase F, Endo-O-glycosidase, α-2(3,6,8,9)-Neuramin-
idase, β(1,4)-Galactosidase, β-N-Acetylglycosaminidase) that
remove N- and O-linked carbohydrates for 1h30 at 37°C, ac-
cording to manufacturer’s recommendations (Enzymatic Pro-
tein Deglycosylation Kit; Sigma-Aldrich). After washing in
1X-PBS, microbiota was stained as described above.
Sorting of IgA-bound microbiota
Gut microbiota obtained from an IgA-deficient patient was in-
cubated with purified mAbs (final concentration, 1 µg/ml) in a
96-well V-bottom plate (107 bacteria/well, 10 wells/mAb) for
30 min at 4°C. After washing with 1X-PBS (10 min, 4,000 ×g,
4°C), cells were stained with goat anti-human IgA-FITC (1/200)
or isotype control antibody (Jackson ImmunoResearch). For
sorting of in vivo IgA1- or IgA2-bound commensal bacteria,
purified fecal microbiota from five healthy donors were thawed,
washed, and directly stained with mouse anti-human IgA1-FITC
or mouse anti-human IgA2 Alexa Fluor 647 (Southern Biotech)
in a 96-well V-bottom plate (107 bacteria/well, five wells/sub-
class) for 20 min at 4°C. After washing, sorting was performed
using a microbiota-dedicated single laser S3 cell sorter (Bio-
Rad). Of note, while flow cytometry analysis is performed on
fixed samples, combined flow sorting and DNA sequencing is
performed on live bacteria in order to allow unbiased and op-
timal DNA extraction. Sorted bacteria (9.105) were collected in
1X-PBS at 4°C, centrifuged (8,000 ×g, 10 min, 4°C), and stored at
−80°C until DNA extraction. Purity for both fractions was sys-
tematically verified after sorting. To check the absence of con-
taminants in flow cytometer fluid lines, sheath fluid was
regularly incubated in Brain-Heart Infusion Broth (BioMérieux)
at 37°C for 7 d.
16S rRNA gene sequencing and analysis
DNA was extracted using Trizol (Ambion), according to the
manufacturer’s instructions. Amplicons of V3-V4 regions of
16S rRNA genes were generated in a PCRmix containing 5 µl of
extracted DNA, 500 U MolTaq 16S (Molzym), 10 mM dNTP
(Invitrogen), and 10 pmol/µl V3-external and V4-external
primers (Table S3) in MolTaq buffer (Molzym) diluted in
DNA-free water (Molzym) for a final volume of 50 µl. 2 µl of
first-round PCR reaction (initial denaturation 95°C 10 min,
95°C 1 min, 54°C 1 min, and 72°C 1 min, 10 times, final exten-
sion 72°C 10 min) was used as template in a second-round PCR
(initial denaturation 95°C 10 min, 95°C 1 min, 66°C 1 min, 72°C
1 min, 10 times, final extension 72°C 10 min) with V3-V4
barcoded primers (Table S3). PCR products were purified us-
ing paramagnetic beads (Agencourt Ampure XP; Beckman
Coulter) and sequenced on a MiSeq instrument (Illumina) in a
multiplexed sequencing run (paired-end 250-nt reads) at the
iGenSeq ICM facility (Institut du Cerveau et de la Moelle Ep-
inière, Paris, France).
Demultiplexed reads were processed using the MG-RAST
analysis pipeline. Sequencing artifacts, host DNA contamina-
tion, and sequences <200 bp in length were removed.
Insufficient-quality reads were discarded (<5% of total reads).
Sequences were then clustered into operational taxonomic units
(OTUs) with a 97% homology using Greengenes database. OTUs
containing only a single sequence were discarded. Previously
published contaminant sequences (Salter et al., 2014) were re-
moved if present in only one sorted fraction and absent from
paired fractions. OTUs detected at >0.1% relative abundance in at
least two samples were finally conserved. This process reduced
the total OTU count from 313 down to 178. The OTU table was
rarefied to the minimum sample’s depth (5,000 reads). The
Shannon index was calculated according to the following equa-
tion: Shannon index = − Σ pi ln(pi), where pi is the relative
abundance of the ith OTU in the dataset. In calculating the EI, we
scored a pseudorelative abundance equal to 0.0001, which was
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the lower limit of detection, if a taxon was not detected in a given
fraction. Specificity of IgA1+IgA2+ targeting was calculated using
the following formula: Number of samples in which OTU had a positive IgA1IgA2 EINumber of samples ,
while specificity of IgA2+ targeting was calculated with the formula:
Number of samples in which OTU had a negative IgA1IgA2 EI
Number of samples , in which IgA1IgA2 EI
refers to log10

IgA1+IgA2+taxon abundance
IgA2+taxon abundance

.
Purification and quantification of IgA
Breast milk was centrifuged at 4,000 ×g for 10 min to remove
the fat content. Aqueous phase was diluted in PBS to achieve pH
7.0 and filtered through a 0.22-µm syringe filter. The breast
milk suspension was loaded onto peptide M/agarose gravity
flow column (InvivoGen) at a flow rate of 0.5 ml/min. The
column was washed with 20 column volumes of 1X-PBS. IgA
was then eluted with 10 ml of 0.1 M glycine (pH 2–3; Sigma-
Aldrich) and immediately neutralized to pH 7.5 with 1 M Tris
(pH 8.5; Sigma-Aldrich). Buffer exchange was performed by
filtration through a 100-kD membrane (Millipore). For free
fecal IgA purification, fecal water were centrifuged twice at
13,000 ×g for 20 min at 4°C to eliminate debris and con-
taminants. After 0.22-µm filtration, IgA was isolated from fecal
water as breast milk. Because the IgA concentration is low in
fecal water, the sample was loaded three times onto the column
to increase efficiency.
For IgA1 and IgA2 purification, serum from five healthy do-
nors was pooled and diluted in 1X-PBS (IgA final concentration,
0.5–1 mg/ml). First, IgA was isolated with a peptide M/agarose
column using the same process as that for breast milk. Then,
purified IgA was loaded onto an immobilized Jacalin column
(Thermo Fisher Scientific). The column was washed with 10
column volumes of PBS; this fraction contained IgA2. The col-
umn was washed again with PBS until absorbance at 280 nm
reached the baseline (Nanovue; GE Healthcare), and 0.1 M α-D-
galactose (Sigma-Aldrich) was added to the column to recover
the bound IgA1. Buffer exchange was performed to remove ga-
lactose from IgA1 and to concentrate IgA2 with a 100-kD ultra-
filtration membrane (Millipore). The purity of the IgA1 and IgA2
fractions was assessed by ELISA. These antibody solutions were
divided into aliquots and frozen at −20°C.
The quantification of IgA in culture supernatants or after
purification was determined using an ELISA quantitation set
(Bethyl), according to the manufacturer’s recommendations.
ELISA
Endocab human IgA kit (Hycult; Biotech) was used to detect LPS
reactivity of mAbs at 0.1 and 1 µg/ml. The experimental proce-
dure followed the manufacturer’s recommendations.
500 ng lipoteichoic acid from S. aureus (Sigma-Aldrich) was
coated onto 96-well Nunc Maxisorp plate (Thermo Fisher Sci-
entific) overnight. Free sites were blocked with 1X-PBS, 1% BSA
for 30min at room temperature. mAbs were incubated for 2 h at
room temperature at 0.1 and 1 µg/ml. After five washes, HRP
anti-human IgA (Bethyl) was added for 1 h, followed by 3,39,5,59
Tetramethylbenzidine substrate revealing reaction (Thermo
Fisher Scientific). Absorbance was measured at 450 nm.
Indirect immunofluorescence assay
HEp-2000 slides (ImmunoConcepts) were incubated with 25 µl
mAb at 2 µg/ml for 25 min in a moist chamber at room tem-
perature. A serum containing IgA anti-DNA served as a positive
control and an irrelevant mAb culture supernatant as a negative
control in all experiments. After washing with PBS, anti-human
IgA FITC (Inova Diagnostics) was added for 25 min in a moist
chamber at room temperature. After washing, fluorescence
patterns were immediately detected with a fluorescent micro-
scope (Leica).
Glycan microarray analysis
Glycan microarray screening using Consortium for Functional
Glycomics (CFG) version 5.3 slides or from Semiotik was per-
formed as previously described (Schneider et al., 2015; von
Gunten et al., 2009; Stowell et al., 2014). The CFG microarray
screening was performed at the National Center for Functional
Glycomics at Beth Israel Deaconess Medical Center (Boston,
MA). Scanning of Semiotik slides was performed on a ScanRI
Microarray Scanner (PerkinElmer) with 5 µm resolution.
The CFG glycan array data are published on the CFG website
(http://www.functionalglycomics.org/glycomics/publicdata/
primaryscreen.jsp). mAbs were diluted in PBS and screened at
10 µg/ml, if not stated otherwise; polyclonal IgA preparations
were diluted in PBS and screened at 200 µg/ml. Commercially
available secretory component (Labforce) was diluted in PBS
and screened at 50 µg/ml. Commercially available human my-
eloma IgA2 (400110; Sigma-Aldrich) or mAb was used as a
control. For the analysis of the CFG slides, the 90th percentile
was used to indicate glycan significantly bound by IgA. For the
analysis of the Semiotik slides, per recommendation of the
manufacturer, RFU values five times higher than the empty spot
negative control were considered positive. The computed ABR
is representative of the quotient of the respective sample RFU
and the corresponding IgA control (Schneider et al., 2015; von
Gunten et al., 2009). ABR intensities lower or equal to one were
defined as unspecific binding. For purposes of analysis, ABR
values lower than one were set to one. To assess preferential
recognition by IgA1 or IgA2, the log10 (IgA2/IgA1) was calcu-
lated. Glycans showing values less than −0.2 was characterized
as being preferentially recognized by IgA1, while values >0.2
were characterized as being preferentially recognized by IgA2
and values equal to or in between −0.2 and 0.2 were considered
as showing no preferential reactivity.
PG and TA purification and dot blot assay
500 ml of overnight culture of S. aureus or S. haemolyticus was
centrifuged. The pellet was suspended and centrifuged twice in
40 ml 50 mM TrisHCl, pH 7.4, 150 mM NaCl, and 1% SDS and
boiled for 10 min. The resulting pellet was suspended in 40 ml
50 mM Tris, pH 7.4, and then sonicated and centrifuged. The
resulting pellet was again treated in 40 ml 50 mM TrisHCl, pH
7.4, 150 mMNaCl, and 1% SDS and boiled for 10 min. PG-TA was
then further purified to eliminate all other known contaminants
by the following successive treatments: digestion with DNase
(1 mg/ml) and RNase (5 mg/ml) in MgSO4 20 mM followed by a
trypsin (10 mg/ml) digestion after addition of CaCl2 (10 mM) for
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12 h The resulting suspension was boiled for 10 min in 1% SDS
and centrifuged. The pellet was then suspended and centrifuged
in (1) H2O, (2) 8 M LiCl2, (3) 100 mM EDTA, (4) H2O (twice), (5)
46% hydrofluoric acid, and finally (6) H2O. TA was recovered
from the hydrofluoric acid supernatant after evaporation.
20 μg of purified PG and TA from S. aureus and S. haemolyticus
was coated on a nitrocellulose membrane (Bio-Rad). The mem-
brane was blocked in 1X-PBS, 5% non-fat milk for 30 min at
room temperature and washed in 1X-PBS, 0.05% Tween 20.
mAbs were then incubated for 30 min at room temperature at
2 µg/ml. After washing, mAbs were detected with HRP-
conjugated goat anti-human IgG used at 1:40,000 (A0170;
Sigma-Aldrich), followed by enhanced chemiluminescence re-
vealing reaction (Clarity Western ECL; Bio-Rad). All incubations
were in 1X-PBS with 5% nonfat milk and washing steps in 1X-
PBS with 0.05% Tween.
Functional cellular assays
Peripheral blood mononuclear cells were isolated from blood
samples by density gradient centrifugation over Ficoll-Paque
(Eurobio). Monocytes for macrophage differentiation were iso-
lated by plastic adherence as follows: peripheral blood mono-
nuclear cells were distributed into a 25-cm2 flask and allowed to
adhere for 1 h at 37°C in RPMI (Gibco) supplemented with 10%
FCS (Biowest). Nonadherent cells were removed, and the ad-
herent monocytes were washed twice with medium, detached
with Versene (Invitrogen), counted, seeded in 96-well U-bottom
plates at a density of 5.104 cells/well, and cultured in RPMI-10%
FCS in the presence of 100 ng/ml human GM-CSF (Miltenyi
Biotec) in a total volume of 100 µl. At day 6, macrophages were
stimulated with 5.105 S. aureus, which had been preincubated
with 0.5 mg/ml of purified IgA1 or IgA2 and washed. After 24 h,
cytokine levels in supernatants were measured using the Cyto-
kine 3-Plex A (IL-6, IL-10, and TNF-α) immunoassay (Quanterix)
relying on a Single Molecule Array (Simoa) technology run on a
HD-1 Analyzer (Quanterix). Working dilutions were 1:500 in
diluent sample. The lower limits of quantification for IL-6, IL-10,
and TNF-α were 5.5, 3.65, and 25.5 pg/ml, respectively.
Statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 6. Nonparametric tests were used whenever necessary; a
Wilcoxon paired rank test was used when comparing paired
groups, a Mann-Whitney test when comparing two independent
groups, and a Kruskal-Wallis test for multiple comparisons.
Significant P values (P < 0.05) are indicated on plots (*, P < 0.05;
**, P < 0.01; ***, P < 0.001). Hierarchical clustering algorithms
were run with Partek software or “R” (The R Foundation for
Statistical Computing, version 3.4.3).
Online supplemental material
Fig. S1 presents the secretory component glycan-binding pattern
and additional characterization of gut-derived IgA reactivity.
Fig. S2 further explores interindividual microbiota variability.
Fig. S3 presents milk-derived IgA reactivity and functional as-
says. Fig. S4 shows additional characterization of monoclonal-
binding patterns. Fig. S5 describes monoclonal self-reactivity.
Table S1 presents Ig gene sequence analysis of dimeric anti-
bodies. Table S2 lists additional demographic data of human
specimens used in this study. Table S3 lists primers used for Ig
and 16S rDNA gene amplification.
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Supplemental material
Figure S1. Gut bacteria segregate into IgAbright and IgAlow fractions in healthy humans. Related to Figs. 1 and 2. (A) The secretory component binds a
modest range of carbohydrates. Glycan reactivity with the secretory component was assessed using glycan microarray technology (660 structures). Repre-
sentative median RFUs are shown. Glycans specifically recognized by secretory component are colored in red. (B) Anti-IgA1 and anti-IgA2 antibodies do not
cross-react. Flow cytometry analysis of IgA1 and IgA2 expression on peripheral B cells from a healthy donor. (C) IgA-coated bacteria split into IgAbright and
IgAlow fractions depending on IgA1 and IgA2 coating. Representative flow cytometry analysis of IgA1 and IgA2 coating in IgAbright-coated bacteria (red lines),
IgAlow-coated bacteria (blue lines), and IgA-unbound bacteria (gray lines). (D) Representative flow cytometry analysis of human gut microbiota stained with
anti-IgA FITC or isotype-matched control antibody (left and central panels). Numbers indicate percentage of positive cells. Data are cumulative from three
independent experiments. Boxes extend from the 25th to the 75th percentiles. Error bars represent minimum and maximum values. P values were defined
using the Mann-Whitney test. ***, P < 0.001. SSC-A, side scatter area. Quantification of IgA-coated bacteria in stool (n = 20) and ileum (n = 5).
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Figure S2. IgA1+IgA2+- and IgA2+-sorted fractions show distinct compositions within the same donor and between donors. Related to Fig. 4. (A)
Sorting strategy of IgA1- and IgA2-coated bacteria (representative of five independent experiments). SSC-A, side scatter area. (B) Relative composition of phyla
in fecal samples (input). Each column corresponds to one healthy donor (HD) sample out of five analysed (HD1 to HD5, as indicated). (C) Genera diversity of
input, IgA1+, and IgA2+ fractions calculated using the Shannon index. Boxes extend from the 25th to the 75th percentiles. Error bars represent minimum and
maximum values. (D) Relative composition of genera in fecal samples (input). Each column corresponds to one sample. The 25 most abundant genera are
shown. (E) Relative abundance of families in input and sorted fractions from five healthy donors. The top 16 most abundant families are shown.
Sterlin et al. Journal of Experimental Medicine S2
Human IgA binds a wide array of commensals https://doi.org/10.1084/jem.20181635
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/217/3/e20181635/851214/jem
_20181635.pdf by U
niversitat Bern user on 06 January 2020
Figure S3. IgA1- and IgA2-coated bacteria promote cytokine production by macrophages. (A) One out of three representative flow cytometric analyses
of human gut microbiota purified from an IgA-deficient donor incubated with breast milk IgA and subsequently with anti-IgA FITC (three independent ex-
periments). Numbers indicate percentage of positive cells. (B) Cytokine levels measured using Simoa technology in supernatants of macrophages incubated for
24 h with heat-killed S. haemolyticus opsonized with IgA1 (blue) or IgA2 (red) or without IgA (gray). The Mann-Whitney test was used to calculate P values; ns,
not significant (n = 3 healthy donors, two independent measurements). Error bars indicate maximum values.
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Figure S4. Human monoclonal IgA bind a broad but nevertheless private pattern of commensals. Related to Fig. 4. (A) Flow cytometric sorting of
intestinal IgA+ memory B cells (defined as CD19+, cell surface IgA+ IgD−). Sort gate among CD19+ B cells is shown. Doublets and dead cells were excluded before
CD19 gating, CD19+ cells were gated among CD45+ cells (not shown). Representative images from three independent sorts are shown. (B) Transduced B cells
exhibited a stable germinal center–like phenotype and maintained IgA expression. Transduced B cells were surface-labeled with anti-CD38, anti-CD95, or anti-
IgA (orange lines) or appropriate isotype antibody controls (gray dotted lines). Representative images of eight monoclonal B cell lines, evaluated in three
independent experiments, are shown. (C)Monoclonal B cell lines produced dimeric IgA. Representative immunoblotting showing high molecular weight dimeric
mAb in nonreducing conditions for mAb 8. Representative image of eight mAbs and two independent experiments are shown. (D) Representative flow cy-
tometric plot of microbiota B stained with anti-IgG Alexa Fluor 647 and anti-IgA FITC. The same experiment was repeated twice. (E) Heatmap diagram of EI of
the 50 most frequent genera frommicrobiota A. Hierarchical clustering grouped mAb+ fractions and genera. (F) Heatmap diagram of EI of the 50most frequent
genera from microbiota B. Hierarchical clustering grouped mAb+ fractions and genera. (G) Flow cytometric analysis of mAb or negative control (mAb− su-
pernatant [left] or irrelevant IgG [right, anti-TNFα IgG1]) staining of pure bacterial strains (two independent experiments).
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Tables S1–S3 are provided online as separate Excel files. Table S1 lists Ig gene analysis of dimeric monoclonal antibodies. Table S2
contains the demographic data of human samples. Table S3 lists primers for Ig and 16s rDNA gene sequence analysis.
Figure S5. Self-reactivity and glycan reactivity of antigen-selected secretory IgA. (A) Median frequency of nonsilent (black) and silent (gray) somatic
mutations in CDRs and VH FWRs in mAb IGH genes (n = 16 mAbs, four independent experiments). (B) Self-reactivity was tested by IFA with HEp-2000 cells: (1)
negative control; (2) positive control: autoimmune human serum containing anti-DNA; (3) purified IgA from fecal water (20 µg/ml); (4) negative staining
representative of 15 nonreactive mAbs; and (5) mAb 4. Representative images of three independent experiments are shown.
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